Cloud Capacity Spectrum Method: Accounting for record-to-record variability in fragility analysis using nonlinear static procedures

This paper investigates a number of computational issues related to the use of nonlinear static procedures in fragility analysis of structures. Such approaches can be used to complement nonlinear dynamic procedures, reducing the computational and modelling effort. Specifically, this study assesses the performance of the Capacity Spectrum Method (CSM) with real (i.e. recorded) ground motions (as opposed to code-based conventional spectra) to explicitly account for record-to-record variability in fragility analysis. The study focuses on single-degree-of-freedom systems, providing a basis for future multi-degree-of-freedom system applications. A case-study database of 2160 inelastic oscillators is defined through parametric backbones with different elastic periods, (yield) base shear coefficients, values of the ductility capacity, hardening ratios, residual strength values and hysteresis rules. These case studies are analysed using 100 real ground motions. An efficient algorithm to perform the CSM with real spectra is proposed, combined with a cloud-based approach (Cloud-CSM) to derive fragility relationships. Simple criteria to solve the issue of multiple CSM solutions (i.e. two or more points on the backbone satisfying the CSM procedure) are proposed and tested. It is demonstrated that the performance point selection can be carried out based on a particularly efficient intensity measure detected via optimal intensity measure analysis. The effectiveness of the proposed Cloud-CSM in fragility analysis is discussed through extensive comparisons with nonlinear time-history analyses, the code-based N2 method, and a simple method involving an intensity measure as a direct proxy for the performance displacement. The Cloud-CSM provides errors lower than ±20% in predicting the median of the fragility curves in most of the analysed cases and outperforms the other considered methodologies in calculating the fragility dispersion

Late recovery with cyclosporine-A of an auto-immune sudden sensorineural hearing loss

Sensorineural hearing loss of immune-mediated origin may be present as a symptom in systemic autoimmune diseases or may occur as a primary disorder without other organ involvement (auto-immune inner ear disease). The diagnosis of auto-immune inner ear disease is still predicated on clinical features and to date specific diagnostic tests are not available. We report a case of right-sided sudden hearing loss in a female patient in which the clinical manifestations, in addition to ANA positivity and hypocomplementaemia allowed us to hypothesize an auto-immune inner ear disease. The immunosuppressive treatment with cyclosporine-A was capable of a recovery of the hearing that, however, occurred progressively with normalization of the hearing function after 1 year of treatment. cyclosporine-A could be proposed as a therapeutic option in case of auto-immune inner ear disease allowing the suspension of corticosteroids that, at high dose, expose patients to potentially serious adverse events

Once daily levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria

Levocetirizine is the pharmacologically active enantiomer of cetirizine. It is a potent histamine H-1 receptor antagonist with anti-inflammatory and antiallergic properties. The review analyses the levocetirizine’s properties in terms of safety and efficacy both in allergic rhinitis and urticarioid syndromes

Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis

Background: Dupilumab is an anti-IL-4Rα antibody used in the treatment of patients with moderate-to-severe atopic dermatitis (msAD). This study explored the potential benefit of dupilumab in perennial allergic rhinoconjunctivitis (PAR) and perennial allergic asthma (PAA) caused by indoor allergens in adults with msAD. Methods: This multicentric, prospective, observational, real-life study included adult patients with msAD who had been treated with dupilumab in 16 Italian care centres. Efficacy outcomes regarding AD, PAR and PAA were collected at baseline and 16 weeks. Safety was also assessed. Results: We enrolled 123 patients with msAD. Between baseline and 16 weeks of treatment, the following measurements decreased statistically significantly: Eczema Area and Severity Index, SCOring AD, Patient-Oriented Eczema Measure, pruritus score, sleep score, Dermatology Life Quality Index and IgE. Dupilumab treatment in patients with comorbid PAR (n = 41) was associated with significant improvements in PAR disease control (measured using a Rhinitis Control Scoring System) and in PAR Quality of life (QoL) (measured using the Rhinoconjunctivitis QoL Questionnaire scores). In 32 patients with comorbid PAA, dupilumab significantly improved PAA control (measured using the Asthma Control Test and five-item Asthma Control Questionnaire scores) and disease-related QoL (measured using the Asthma QoL Questionnaire scores). Thirty-five patients (28.5%) developed conjunctivitis during the study period. Conclusion: These results support the benefits of dupilumab for adult patients with PAR and/or PAA associated with msAD

acute allergic reactions to anisakis simplex after ingestion of anchovies

symptoms after ingestion of esh. The etiological role of The study population also comprised 33 controls grouped as: Anisakis simplex was evaluated in 49 adult subjects with ‐ 24 individuals who never ate raw or undercooked esh during acute allergic symptoms after ingestion of anchovies. their lifetime, of whom 5 were non-atopic healthy subjects, Serum-specie c IgE and prick tests to anchovy were nega- 9 were non-atopic patients with physical urticarias, and 10 tive in each patient. Specie c IgE reactions to Anisakis had a personal history of atopy (atopic dermatitis, allergic asthma and/or rhinitis); were positive in 45 patients and skin tests in 43. Only 3 ‐ 9 regular consumers of raw-esh products with no antepatients with allergy to the nematode were atopic. cedents of atopy or any allergic reactions. However, IgE responses to Anisakis were also observed After an adequate washout period from active treatments, in in habitual consumers of raw e sh, without any clinical vivo tests were performed in both patients and controls: manifestations, suggesting that the relevance of results of ‐ skin-prick tests (SPTs) with common aeroallergens conventional tests has to be interpreted on the basis of (Stallergenes Italia, Saronno, Varese, Italy)

Choroid plexus enlargement is associated with neuroinflammation and reduction of blood brain barrier permeability in depression.

BACKGROUND: Recent studies have shown that choroid plexuses (CP) may be involved in the neuro-immune axes, playing a role in the interaction between the central and peripheral inflammation. Here we aimed to investigate CP volume alterations in depression and their associations with inflammation. METHODS: 51 depressed participants (HDRS score > 13) and 25 age- and sex-matched healthy controls (HCs) from the Wellcome Trust NIMA consortium were re-analysed for the study. All the participants underwent full peripheral cytokine profiling and simultaneous [11C]PK11195 PET/structural MRI imaging for measuring neuroinflammation and CP volume respectively. RESULTS: We found a significantly greater CP volume in depressed subjects compared to HCs (t(76) = +2.17) that was positively correlated with [11C]PK11195 PET binding in the anterior cingulate cortex (r = 0.28, p = 0.02), prefrontal cortex (r = 0.24, p = 0.04), and insular cortex (r = 0.24, p = 0.04), but not with the peripheral inflammatory markers: CRP levels (r = 0.07, p = 0.53), IL-6 (r = -0.08, p = 0.61), and TNF-α (r = -0.06, p = 0.70). The CP volume correlated with the [11C]PK11195 PET binding in CP (r = 0.34, p = 0.005). Integration of transcriptomic data from the Allen Human Brain Atlas with the brain map depicting the correlations between CP volume and PET imaging found significant gene enrichment for several pathways involved in neuroinflammatory response. CONCLUSION: This result supports the hypothesis that changes in brain barriers may cause reduction in solute exchanges between blood and CSF, disturbing the brain homeostasis and ultimately contributing to inflammation in depression. Given that CP anomalies have been recently detected in other brain disorders, these results may not be specific to depression and might extend to other conditions with a peripheral inflammatory component

Drug induced exfoliative dermatitis: State of the art

Drug induced exfoliative dermatitis (ED) are a group of rare and severe drug hypersensitivity reactions (DHR) involving skin and usually occurring from days to several weeks after drug exposure. Erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the main clinical presentations of drug induced ED. Overall, T cells are the central player of these immune-mediated drug reactions. Here we provide a systematic review on frequency, risk factors, pathogenesis, clinical features and management of patients with drug induced ED

Final report of EURAMET.M.G-K3 regional comparison of absolute gravimeters

The regional key comparison of absolute gravimeters, EURAMET.M.G-K3 and the simultaneously organized additional comparison, was held in Germany at the Geodetic Observatory Wettzell of the German Federal Agency for Cartography and Geodesy in the spring of 2018.Here we present the list of the participants who actually performed measurements during the comparison, the data submitted by the operators as well as the results of the determination of the gravity as a function of height at the comparison sites. The measurement strategy is briefly discussed and the results of the data harmonization is documented. Finally, the results of the constrained least squares adjustment are presented including the degrees of equivalence of each gravimeter and the key comparison reference values.Main textTo reach the main text of this paper, click on Final Report. Note that this text is that which appears in Appendix B of the BIPM key comparison database kcdb.bipm.org/.The final report has been peer-reviewed and approved for publication by the CCM, according to the provisions of the CIPM Mutual Recognition Arrangement (CIPM MRA).Export citation and abstract BibTeX RIS